Natera, Inc. (NTRA)
NASDAQ: NTRA · Real-Time Price · USD
167.88
+5.78 (3.57%)
At close: Nov 20, 2024, 4:00 PM
169.88
+2.00 (1.19%)
Pre-market: Nov 21, 2024, 7:01 AM EST

Company Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test.

In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics to validate and launch tests.

The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners.

It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.

The company was founded in 2003 and is headquartered in Austin, Texas.

Natera, Inc.
Natera logo
Country United States
Founded 2003
IPO Date Jul 2, 2015
Industry Diagnostics & Research
Sector Healthcare
Employees 3,293
CEO Steven Chapman

Contact Details

Address:
13011 McCallen Pass, Building A
Austin, Texas 78753
United States
Phone 650 980 9190
Website natera.com

Stock Details

Ticker Symbol NTRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001604821
CUSIP Number 632307104
ISIN Number US6323071042
Employer ID 01-0894487
SIC Code 8071

Key Executives

Name Position
Steven Leonard Chapman Chief Executive Officer and Director
Dr. Matthew Rabinowitz Ph.D. Co-Founder and Executive Chairman
Michael B. Brophy M.B.A. Chief Financial Officer
Daniel Rabinowitz L.L.M. Secretary and Chief Legal Officer
John Fesko President and Chief Business Officer
Jonathan Sheena M.Eng. Co-Founder and Director
Olesya A. Anisimova CPA Chief Accounting Officer
Rishi Kacker Chief Technology Officer
Eric A. Evans Chief Scientific Officer
Jerry Diffley Chief Compliance and Privacy Officer

Latest SEC Filings

Date Type Title
Nov 19, 2024 144 Filing
Nov 15, 2024 144 Filing
Nov 15, 2024 144 Filing
Nov 14, 2024 144 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 144 Filing
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 31, 2024 144 Filing